INTRODUCTION
The history of labour induction dated back to Hippocrates " original descriptions of mammary stimulation and mechanical dilatation of the cervical canal. 1 Conventionally and essentially arbitrarily, a pregnancy is considered to be "prolonged" after 41 (+0) weeks of gestation. Prolonged pregnancies involve 15-20 % of pregnant women and post term pregnancies [>42(+0) weeks] approximately 1%. In prolonged pregnancies, especially the emergency caesarean section rate is multiplied by 1.5 (Grade B). From 37 (0-6) to 43 (0-6) weeks, the risk of perinatal mortality increase regularly, from 0.7% to 5.8%. Meconium aspiration syndrome is responsible for substantial morbidity and mortality, and its incidence increases regularly between 38 (+0) and 42 (+6) weeks, from 0.24% to 1.42% (Grade  B) . Similarly, the risks of neonatal acidosis ( Grade B), 5-minutes APGAR score less than 7 (Grade B) and admissions to neonatal intensive care units (Grade B) increase progressively between 38 (+0) and 42 (+6) weeks. These risks appear to double for post-term growth-restricted newborns (Grade C). 2 Unpublished data from the WHO global survey on maternal and perinatal death which included 373 health-care facilities in 24 countries and nearly 300,000 deliveries, showed that 9.6% of the deliveries involved labour induction. 3 Recent studies have suggested that by continuing pregnancies beyond 41 weeks, there is a statistically significant higher perinatal morbidity and mortality as well as an increased risk to the mother. 4, 5 Thus, there is a growing body of evidence suggesting the elective induction of labour at 41 completed weeks of gestation instead of expectant management. [6] [7] [8] In 1968, Karim & colleagues were the first to report the use of prostaglandins for labour induction. 9 Since then, the use of prostaglandins, in different varieties and forms of administration, has become a common method of labour induction. 10 More recently, a synthetic prostaglandin analogue misoprostol has gained acceptance as an effective and safe method of labour induction. 11 Several studies have demonstrated a higher efficacy of vaginally administered misoprostol compared to vaginal dinoprostone for both cervical ripening and labour induction at the usual recommended doses. 12 However, it is difficult to interpret previously published studies comparing misoprostol with dinoprostone for induction of labour since majority of them have included both complicated and uncomplicated pregnancies as well as a wide gestational age (GA) range (37-42 weeks). [13] [14] [15] Moreover, to reduce the risk of side effects, one can either decrease the dose of the drug or prolong the dosage interval. In addition, Alexander et al, have recently shown that in prolonged pregnancies it was not the induction per se that would increase the risk for caesarean section (CS), but was the patients-related risk factors such as undilated cervix. 16 This study was undertaken to compare the efficacy of vaginal misoprostol with that of intracervical dinoprostone in a well-homogenized cohort of prolonged pregnancies with an unfavourable cervix (Modified Bishop"s score <5) and without pregnancy complications.
METHODS
192 women with prolonged pregnancies at 288 th day of gestation were recruited in between January 1, 2013 and December 31, 2014 for the study at the labour ward in the department of Gynae and Obst, NRS medical college, Kolkata 700014, a tertiary care centre in West Bengal, India with about 10,000 deliveries a year. The ethical committee approved the study and all participants gave their written informed consent. A sequence from a computerized random number generator was used for the allocation of patients to each group: 96 women in misoprostol group (Group A) and 96 women in dinoprostone group (Group B). A Sample size calculation was performed on the assumption that misoprostol would differ more than 17% from dinoprostone in terms of induction to delivery interval. The average delivery interval in our institute is 18 hours approximately. On the basis of a type I error of 0.05 and a power of 80% (type II error 0.2), 96 women in both trial arm were required. After exclusions from intention-to-treat analysis, secondary "protocol compliant" analysis was done with 94 women in the misoprostol group and 91 women in dinoprostone group ( Figure 1 ).
Inclusion criteria
Women allocated to the misoprostol group (Group A) received 25 mcgs of misoprostol tablet placed in the posterior fornix and was administered every 4 hours for a maximum of six doses. Women allocated to the dinoprostone group received 0.5 mg of dinoprostone gel intracervically every six hours for a maximum of three doses. Intravaginal oxytocin augmentation was used after spontaneous or artificial rupture of membranes without adequate uterine contractions or failure to progress in active phase of labour. Partograph was performed from the moment women were considered to be in active phase of labour along with continuous fetal heart rate and uterine activity monitoring using CTG machines. Hyperstimulation syndrome was diagnosed whenever there was either uterine tachysystole (>5 contractions per 10 minutes) or hypertonus (when one contraction lasted more than 2 minutes) was associated with the presence of non reassuring fetal heart rate patterns as persistent or recurring episodes of severe variable decelerations, late decelerations, prolonged fetal bradycardia or a combination of decreased beat-to-beat variability and a decelerative pattern. The primary outcome measures were time from induction to delivery (IDI), incidence of delivery within 12 hours and 24 hours and mode of delivery whether vaginal or caesarean section. The secondary outcome measures were maternal side effects and need of neonatal resuscitation with evaluation of APGAR score at 1 minute and 5 minutes requiring NICU admission within 24 hours of delivery.
Statistical analysis was performed using SPSS version II software. The Chi-square tests (x 2 ) and the student-T tests were performed for nominal variations and normal distributed metric variables respectively. All tests were two tailed with a confidence level of 95% (p<0.05). Values are expressed as mean +/-standard error (SEM) and the percentage of total number of samples.
RESULTS
The two groups were comparable in terms of demographic characteristics such as parity ( Table 3 showing labour events as follows: IDI were statistically significantly different between the groups both in primigravida (t=17.38, df =183, p<0.05) and in multigravida (t=47.6, df =183, p<0.05). The time to reach active phase of labour from the time of starting of induction of labour was significantly less in misoprostol group (t=73.64, df=183, p<0.05) while need for oxytocin augmentation was significantly more in dinoprostone group (x 2 =30.99,p<0.05). The incidence of spontaneous rupture of membranes were significantly more in group A (x 2 =13.08, p<0.05). The need of repeated doses were also statistically significantly different between two groups (x 2 = 8.46, df=2, p<0.05). The occurrence of meconium stained amniotic fluid (MSAF), abnormal fetal heart rate changes and incidences of uterine hyperstimulation syndrome were more in misoprostol group than dinoprostone group but were not statistically significant.
In Table 4 , the secondary outcomes showing adverse effects due to prostaglandin use were seen in 8.51% cases of misoprostol group only and no one in the dinoprostone group was suffering from G.I side effects like vomiting, diarrhoea etc. There was only one case of atonic PPH occurred in dinoprostone group and she received blood transfusion along with uterotonic drugs without surgical intervention. The incidences of vaginal tear were more in group A (5.32% versus 2.19%, x 2 = 1.24, p>0.05) and puerperal sepsis occurred more in group B (4.25%versus 8.79%, x 2 = 2.15, p>0.05). Significantly different mean birth weight of newborns were seen between the groups (2775+/-530grams vs 2532+/-450grams; t=3.36, df=183, p<0.05). The need for neonatal resuscitation was significantly more in group A (x 2 = 5.25, p<0.05) while more neonates in the misoprostol group had lower APGAR score of <7 at one minute (x 2 = 4.67, p<0.05) and at 5 minutes (x 2 = 1.75, p=0.186) needed NICU admissions but that difference was not statistically significant when compared to dinoprostone group. 
DISCUSSION
Induction of labour is more widely used than ever before, nowadays, for both maternal and fetal indication. 18 One of the most common indications is prolonged pregnancy. 19 Women may experience distress when labour has not started by the expected date and obstetricians have to withstand pressure from these patients as well as the temptation to use prostaglandins earlier. Appropriate evaluation of the pregnancy and consultation with such patients will lead to the correct selection to those who will benefit most from a labour induction, thus eliminating the risk of post maturity to the fetus without inducing fetal distress during labour. In these carefully selected cohort of patients, misoprostol at the dose used not only shortened the time between induction and delivery (10.8 hrs vs 18.4hrs) in comparison with dinoprostone but this result was achieved with low CS rate (12.76% vs 23.07%) respectively. A difference of 10% in favour of misoprostol, although not statistically significant, might have clinical importance in terms of patient health and cost effectiveness as supported by a study by Sanchez -Ramos et al. 20 With misoprostol, there was an increased incidence of MSAF as well as hyperstimulation syndrome than dinoprostone but the CS rate is lower and though APGAR score <7 at 5 minutes with NICU admission were higher but that are not statistically significant, a finding in favour of misoprostol not seen in previous studies like a study by Blanchard K et al. 21 As with other studies, lesser number of participants with misoprostol induction required augmentation of labour with oxytocin as compared to dinoprostone gel. 22 So, it is evident that vaginal misoprostol is more effective than intracervical dinoprostone gel.
CONCLUSIONS
Vaginally administered tablet misoprostol is a safe and more effective method of induction of labour when compared with intracervical dinoprostone gel in prolonged pregnancies beyond 41 weeks of gestation as adverse perinatal outcomes are not disproportionately increased if timely intervention is done with adequate and appropriate surveillance.
